Literature DB >> 23428905

Hepatocellular alterations and dysregulation of oncogenic pathways in the liver of transgenic mice overexpressing growth hormone.

Johanna G Miquet1, Thomas Freund, Carolina S Martinez, Lorena González, María E Díaz, Giannina P Micucci, Elsa Zotta, Ravneet K Boparai, Andrzej Bartke, Daniel Turyn, Ana I Sotelo.   

Abstract

Growth hormone (GH) overexpression throughout life in transgenic mice is associated with the development of liver tumors at old ages. The preneoplastic pathology observed in the liver of young adult GH-overexpressing mice is similar to that present in humans at high risk of hepatic cancer. To elucidate the molecular pathogenesis underlying the pro-oncogenic liver pathology induced by prolonged exposure to elevated GH levels, the activation and expression of several components of signal transduction pathways that have been implicated in hepatocellular carcinogenesis were evaluated in the liver of young adult GH-transgenic mice. In addition, males and females were analyzed in parallel in order to evaluate sexual dimorphism. Transgenic mice from both sexes exhibited hepatocyte hypertrophy with enlarged nuclear size and exacerbated hepatocellular proliferation, which were higher in males. Dysregulation of several oncogenic pathways was observed in the liver of GH-overexpressing transgenic mice. Many signaling mediators and effectors were upregulated in transgenic mice compared with normal controls, including Akt2, NFκB, GSK3β, β-catenin, cyclin D1, cyclin E, c-myc, c-jun and c-fos. The molecular alterations described did not exhibit sexual dimorphism in transgenic mice except for higher gene expression and nuclear localization of cyclin D1 in males. We conclude that prolonged exposure to GH induces in the liver alterations in signaling pathways involved in cell growth, proliferation and survival that resemble those found in many human tumors.

Entities:  

Keywords:  GSK3β; NFκB; c-fos; c-jun; c-myc; cyclin D1; cyclin E; growth hormone; liver; β-catenin

Mesh:

Substances:

Year:  2013        PMID: 23428905      PMCID: PMC3646861          DOI: 10.4161/cc.24026

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  80 in total

Review 1.  The oncogenic potential of growth hormone.

Authors:  Jo K Perry; B Starling Emerald; Hichem C Mertani; Peter E Lobie
Journal:  Growth Horm IGF Res       Date:  2006-11-13       Impact factor: 2.372

Review 2.  Does growth hormone cause cancer?

Authors:  P J Jenkins; A Mukherjee; S M Shalet
Journal:  Clin Endocrinol (Oxf)       Date:  2006-02       Impact factor: 3.478

3.  Overexpressed growth hormone (GH) synergistically promotes carcinogen-initiated liver tumour growth by promoting cellular proliferation in emerging hepatocellular neoplasms in female and male GH-transgenic mice.

Authors:  K J Snibson; P S Bhathal; T E Adams
Journal:  Liver       Date:  2001-04

4.  Dynamic, sex-differential STAT5 and BCL6 binding to sex-biased, growth hormone-regulated genes in adult mouse liver.

Authors:  Yijing Zhang; Ekaterina V Laz; David J Waxman
Journal:  Mol Cell Biol       Date:  2011-12-12       Impact factor: 4.272

5.  New murine model for hepatocellular carcinoma: transgenic mice expressing metallothionein-ovine growth hormone fusion gene.

Authors:  J M Orian; K Tamakoshi; I R Mackay; M R Brandon
Journal:  J Natl Cancer Inst       Date:  1990-03-07       Impact factor: 13.506

6.  Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver.

Authors:  Axel Behrens; Maria Sibilia; Jean-Pierre David; Uta Möhle-Steinlein; François Tronche; Günther Schütz; Erwin F Wagner
Journal:  EMBO J       Date:  2002-04-02       Impact factor: 11.598

Review 7.  Proliferative drive and liver carcinogenesis: too much of a good thing?

Authors:  Narci C Teoh
Journal:  J Gastroenterol Hepatol       Date:  2009-12       Impact factor: 4.029

8.  Transgenic mice overexpressing GH exhibit hepatic upregulation of GH-signaling mediators involved in cell proliferation.

Authors:  Johanna G Miquet; Lorena González; Marina N Matos; Christina E Hansen; Audreen Louis; Andrzej Bartke; Daniel Turyn; Ana I Sotelo
Journal:  J Endocrinol       Date:  2008-05-14       Impact factor: 4.286

Review 9.  Accelerated growth and visceral lesions in transgenic mice expressing foreign genes of the growth hormone family: an overview.

Authors:  R Wanke; W Hermanns; S Folger; E Wolf; G Brem
Journal:  Pediatr Nephrol       Date:  1991-07       Impact factor: 3.714

Review 10.  IkappaB kinase beta (IKKbeta/IKK2/IKBKB)--a key molecule in signaling to the transcription factor NF-kappaB.

Authors:  Johannes A Schmid; Andreas Birbach
Journal:  Cytokine Growth Factor Rev       Date:  2008-03-04       Impact factor: 7.638

View more
  22 in total

1.  Increased ATP synthesis might counteract hepatic lipid accumulation in acromegaly.

Authors:  Paul Fellinger; Peter Wolf; Lorenz Pfleger; Patrik Krumpolec; Martin Krssak; Kristaps Klavins; Stefan Wolfsberger; Alexander Micko; Patricia Carey; Bettina Gürtl; Greisa Vila; Wolfgang Raber; Clemens Fürnsinn; Thomas Scherer; Siegfried Trattnig; Alexandra Kautzky-Willer; Michael Krebs; Yvonne Winhofer
Journal:  JCI Insight       Date:  2020-03-12

Review 2.  Growth hormone in the tumor microenvironment.

Authors:  Vera Chesnokova; Shlomo Melmed
Journal:  Arch Endocrinol Metab       Date:  2019 Nov-Dec       Impact factor: 2.309

3.  Exposure to growth hormone is associated with hepatic up-regulation of cPLA2α and COX.

Authors:  Verónica G Piazza; María E Matzkin; Nadia S Cicconi; Nadia V Muia; Sofía Valquinta; Gregorio J Mccallum; Giannina P Micucci; Thomas Freund; Elsa Zotta; Lorena González; Mónica B Frungieri; Yimin Fang; Andrzej Bartke; Ana I Sotelo; Johanna G Miquet
Journal:  Mol Cell Endocrinol       Date:  2020-04-04       Impact factor: 4.102

4.  Male bovine GH transgenic mice have decreased adiposity with an adipose depot-specific increase in immune cell populations.

Authors:  Fabian Benencia; Stephanie Harshman; Silvana Duran-Ortiz; Ellen R Lubbers; Edward O List; Lara Householder; Mawadda Al-Naeeli; Xiaoyu Liang; Lonnie Welch; John J Kopchick; Darlene E Berryman
Journal:  Endocrinology       Date:  2014-12-18       Impact factor: 4.736

5.  GH/STAT5 signaling during the growth period in livers of mice overexpressing GH.

Authors:  Carolina S Martinez; Verónica G Piazza; María E Díaz; Ravneet K Boparai; Oge Arum; María C Ramírez; Lorena González; Damasia Becú-Villalobos; Andrzej Bartke; Daniel Turyn; Johanna G Miquet; Ana I Sotelo
Journal:  J Mol Endocrinol       Date:  2015-02-17       Impact factor: 5.098

6.  Growth Hormone Induces Colon DNA Damage Independent of IGF-1.

Authors:  Vera Chesnokova; Svetlana Zonis; Robert J Barrett; John P Gleeson; Shlomo Melmed
Journal:  Endocrinology       Date:  2019-06-01       Impact factor: 4.736

7.  Metabolic adaptation of short-living growth hormone transgenic mice to methionine restriction and supplementation.

Authors:  Holly M Brown-Borg; Sharlene Rakoczy; Joseph A Wonderlich; Kurt E Borg; Lalida Rojanathammanee
Journal:  Ann N Y Acad Sci       Date:  2018-04       Impact factor: 5.691

8.  Mitogenic signaling pathways in the liver of growth hormone (GH)-overexpressing mice during the growth period.

Authors:  Carolina S Martinez; Verónica G Piazza; Lorena González; Yimin Fang; Andrzej Bartke; Daniel Turyn; Johanna G Miquet; Ana I Sotelo
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 9.  Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications.

Authors:  John J Kopchick; Edward O List; Bruce Kelder; Elahu S Gosney; Darlene E Berryman
Journal:  Mol Cell Endocrinol       Date:  2013-09-11       Impact factor: 4.102

10.  Growth hormone is permissive for neoplastic colon growth.

Authors:  Vera Chesnokova; Svetlana Zonis; Cuiqi Zhou; Maria Victoria Recouvreux; Anat Ben-Shlomo; Takako Araki; Robert Barrett; Michael Workman; Kolja Wawrowsky; Vladimir A Ljubimov; Magdalena Uhart; Shlomo Melmed
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.